Daraxonrasib is showing late-line efficacy in metastatic pancreatic ductal adenocarcinoma, with the phase III RASolute-302 trial reporting a doubling of median overall survival versus chemotherapy in second-line patients. The pan-RAS inhibitor added a significant survival signal in a setting where outcomes remain poor despite standard cytotoxic approaches. The trial results position daraxonrasib as a notable contender in the increasingly competitive RAS-pathway space, where combinations and sequencing strategies are central to differentiating next-generation agents. For clinicians, the key read-through is the potential shift in second-line expectations if the benefit holds across endpoints and safety profiles reported by the study. For the broader industry, it reinforces the viability of targeting RAS signaling beyond KRAS-specific approaches.